Multiple neuropeptides have been identified that appear to modulate pathways within the hypothalamus to control appetite. Identifying potential therapeutic targets for the treatment of obesity ...

The Prader Willi Syndrome (PWS) has been described clinically as: obesity, hypotonia, acromicria, and mental retardation. The eating disorder is currently thought to have a hypothalamic basis.

Rhythm Pharmaceuticals (RYTM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

The hypothalamus, a critical brain structure ... with female offspring exhibiting greater susceptibility to metabolic ...

Diagnosis Panhypopituitarism, hypothalamic obesity and hyperinsulinemia following craniopharyngioma therapy. Management Severe caloric restriction, octreotide, and pituitary hormone replacement ...

Analyst Whitney Ijem of Canaccord Genuity maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report), retaining the price ...

The drug developer is testing setmelanotide for the treatment of acquired hypothalamic obesity. Rhythm added that the FDA has cleared the company to begin clinical testing of its drug candidate RM ...

long-acting MC4R peptide and small molecule compounds aimed at treating general obesity, weight loss management, and rare MC4R pathway diseases like hypothalamic obesity." Palatin is currently ...

Real-world data showed mean BMI decrease of 12.8% in adult patients with acquired hypothalamic obesity (N=8) at three months on setmelanotide therapy; mean BMI decrease of 21.3% in patients (n=5 ...